Want to join the conversation?
$CELG 2Q15 Call: Received approval for REVLIMID for the expanded use in patients newly diagnosed with multiple myeloma in the U.S. and Europe. Received approval for POMALYST in Japan for the treatment of relapsed and refractory multiple myeloma (RRMM).
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.